anti-CD7 CAR-T cell

Anti-CD7 CAR-T cell therapy is a type of adoptive cellular immunotherapy designed to treat CD7-positive hematologic malignancies, such as T-cell acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LBL). CD7 is a transmembrane glycoprotein highly expressed in the majority of T-cell malignancies but also on normal T cells and natural killer (NK) cells. A major challenge in developing anti-CD7 CAR-T cells is "fratricide," where the CAR-T cells attack each other because they also express CD7. Strategies to overcome this include genomic editing (e.g., CRISPR/Cas9) to knock out the CD7 gene in the CAR-T cells or using "naturally selected" CD7-negative T cells. Various developers, including SenlangBio, Gracell Biotechnologies, and PersonGen Biotherapeutics, are investigating different versions of this therapy, including autologous, allogeneic, and donor-derived products.

Other names

CD7 CAR-TCD-7 CAR-TCD 7 CAR-TCD7-targeted CAR-TCD-7-targeted CAR-TCD 7-targeted CAR-Tanti-CD7 CAR-Tanti-CD-7 CAR-Tanti-CD 7 CAR-Tanti-CD7 chimeric antigen receptor T-cell therapyanti-CD-7 chimeric antigen receptor T-cell therapyanti-CD 7 chimeric antigen receptor T-cell therapy